Former Telomolecular CEO, Matthew Sarad, plans a series of experiments to demonstrate the power of nanotechnology based regenerative medicines.
(PRWEB) September 11, 2009 -- Long-time financier and CEO of U.S. biotechnology companies, Mr. Matthew Sarad, has announced plans to attempt to rejuvenate living animals with advanced nanotechnologies developed by his labs. The goal of the project is to demonstrate that a combination of new nanotechnology based therapeutics can be used to "make young again" moderately-aged large animals that are genetically similar to man. The experiment will be considered successful if it doubles the animal's lifespan and decreases its chronological age by greater than 40%. Mr. Sarad is currently seeking the support of university partners, collaborators, and benefactors to help meet the program goals of rejuvenating three adult animals by mid 2011.
Mr. Sarad has been a leader in the nanotechnology field. In the past he employed top scientists from Harvard, Stanford, MIT, MD Anderson Cancer Center, and UC Davis among others. Some of the therapeutic nanotechnologies that he pioneered are being studied in animals at some of the country's largest hospitals and research centers including a nanotechnology based therapeutic for treating post stroke reperfusion injury and anti-cancer therapeutics that show excellent safety profiles and higher remission rates.
While acting as CEO of Telomolecular Mr. Sarad demonstrated that it is possible to rejuvenate tissues by delivering the whole telomerase protein to cells with a nanotechnology based drug delivery system. The delivery of telomerase repairs degraded chromosomal telomeres which affect the function and activity of a litany of age-associated genes that control the age characteristics and replicate lifespan of cells. The shortening of telomeres plays a role in the development of certain age-associated dise
Copyright©2009 Vocus, Inc.
All rights reserved